


# NCI SBIR AND YOUR STATE:

## NORTH CAROLINA



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$20.5 million** in funding across **16 Phase II SBIR/STTR grants** to small businesses in North Carolina. The following economic impact estimates quantify the program's contributions to the state's economy:

	<b>\$123.1M</b>	<b>IN TOTAL DIRECT SALES</b>
	<b>\$499.3M</b>	<b>IN TOTAL ECONOMIC IMPACT</b>
	<b>2K</b>	<b>JOBS CREATED</b>
	<b>\$15.6M</b>	<b>IN STATE &amp; LOCAL TAXES COLLECTED</b>
	<b>12</b>	<b>COMPANIES WITH SALES</b>

*\*These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in North Carolina: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$120.5M in funding across all grants to oncology-focused small businesses in the state.*

### Success stories include: **G1 THERAPEUTICS, INC.**

G1 Therapeutics used SBIR funding to create COSELA™, a drug that reduces chemotherapy-induced bone marrow suppression in adults with extensive-stage small cell lung cancer. It gained FDA approval in February 2021, and completed a \$405 million acquisition agreement with Pharmacosmos in 2024.

### **CIVATECH ONCOLOGY, INC.**

Using SBIR funding, CivaTech developed CivaSheet™, an implantable device for targeted radiation therapy that protects healthy tissue while treating tumors with complex surgical margins. It received FDA approval in August 2014.

**The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to [ncisbir@mail.nih.gov](mailto:ncisbir@mail.nih.gov).**